Euro-celtique S.a.

Glaxo Group Limited

Numedicus Limited

Psioxus Therapeutics Limited

Dynogen Pharmaceuticals, Inc.

Arachnova Therapeutics Ltd.

Healx Limited

David J Cavalla

Mark Chasin

Peter Hofer

Alexander W Oxford

Peter C North

Lloyd Jay Dolby

Andre Gehrig

Peter Wintergerst

Richard William Frith

David E Bays

Robert William Gristwood

William L Mitchell

Andrew C Mansfield

Anddre Gehrig

Peter Wintergest

Lesley Walton

John W Whitehead

Derek J Black

Tricyclic dibenzothiazepine compounds for use in the treatment of respiratory depression.

Treatment of respiratory depression

A compound of formula I: or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R, R, R, R, R, R, X and m are as defined herein.

Dibenzothiazepine derivatives and their use in the treatment of CNS disorders

The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propranolol, tertatolol or bopindolol are preferred for this purpose.

Treatment of cachexia

Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of functional bowel disorder.

4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder

4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)pyrimidine or a salt thereof is useful for the treatment of urinary incontinence.

Use of 4-(2-Flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidine for treating of urinary incontinence

Aryl isoguanines

Purine derivatives having phosphodiesterase iv inhibition activity

Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE III inhibition.

Benzoxazoles

6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity

Purine derivatives having phosphodiesterase IV inhibition activity

Hypoxathine compounds

Disclosed is a compound selected from the group consisting of 1,3,8-triethyl-2,6-dithioxanthine; 1,3,8-triethyl-2-thioxanthine; 8-cyclopropyl-1-ethyl-3-(2-methyl-butyl)-6-thioxanthine; 1,3-diethyl-8-isopropyl-6-thioxanthine; 8-cyclopropyl-1,3-dipropyl-6-thioxanthine; 8-isopropyl-1,3-dipropyl-6-thioxanthine; 1,3-diethyl-8-cyclopropyl-2,6-dithioxanthine; 1-(4-chlorobenzyl)-3-ethyl-8-isopropyl-6-thioxanthine; and 8-cyclopropyl-1,3-diethyl-6-thioxanthine. Also disclosed is a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a compound selected from the group above. Also disclosed is a method of effecting PDE IV inhibition which comprises administering to a patient suffering from a disease or disorder selected from the group consisting of asthma, allergies, PDE IV modulated inflammation, and depression, a therapeutically effective amount of a compound selected from the group above.

Trisubstituted thioxanthines

With the above and other objects in view, the present invention comprises compounds having the general formula (I):

3-(arylalkyl) xanthines

Novel compounds which are effective PDE IV inhibitors are disclosed. These compounds have the general structure of:

Phenyl-triazole compounds for PDE-IV inhibition

Growing community of inventors

Cambridge, United Kingdom

David J Cavalla